NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Soleno Therapeutics, Inc. (SLNO) Stock Analysis

Soleno Therapeutics, Inc. (SLNO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

SLNO

$53.01

$0.00 (0.00%)

Last trade May 18, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SLNO with… →

SLNO Key Statistics

As of May 18, 2026
Trading
Open
$53.01
Previous Close
$53.01
52-Week Range
29.43–90.32
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−2.22
Valuation
Market Cap
$2.76B
P/E Ratio
27.47
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
9.69
EPS (ttm)Profit attributable to each share over the last twelve months.
1.93
Financials (FY)
Profit marginThe share of revenue left as profit after all costs and taxes.
33.70%
1-Year Return
−29.33%
Dividend and dates
Avg Volume
3.63M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SLNO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+14.49%
2025+3.00%
2024 (partial year)−0.55%

As of May 18, 2026.

SLNO Valuation vs Biotechnology Median

Median of 656 stocks
MetricSLNOBiotechnology medianvs median
P/E27.4712.57119% above
P/S ratio9.6915.2636% below
Profit margin33.70%0.00%33.7 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Soleno Therapeutics, Inc. (SLNO) carries a market capitalisation of $2.76B. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 182 employees.

Over the past 52 weeks the price has ranged from $29.43 to $90.32. SLNO last closed at $53.01 on May 18, 2026. The close was unchanged from the previous session. The latest close sits 80.12% above that 52-week low.

Financial Health

Trailing twelve-month revenue on file is $285.01M. The reported profit margin is 33.7%. That is 33.7 percentage points above the Biotechnology median of 0%. Trailing earnings per share are 1.93.

Valuation Assessment

The trailing P/E ratio stands at 27.47. That is 118.54% above the Biotechnology median of 12.57. Measured against sales, the shares trade at 9.69 times revenue. On price-to-sales that is 36.49% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Beta against the wider market is reported at −2.22. Annualized volatility over the trailing 1 year is 69.18%. Over the trailing twelve months the price has returned −29.33%.

Growth & Income

No dividend is on file for SLNO.

So far in 2026 the price is +14.49%. The record holds one complete calendar year, 2025, which returned +3.00%.

Peer Comparison

Soleno Therapeutics, Inc. (SLNO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Soleno Therapeutics, Inc. SLNO $2.76B 27.5
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Soleno Therapeutics, Inc. trades at a P/E of 27.5.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of May 18, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California. As of May 18, 2026, Soleno Therapeutics, Inc. operates as a subsidiary of Neurocrine Biosciences, Inc.

Visit website →